Ionis Pharmaceuticals Secures FDA Orphan Drug Designation For Rare Epilepsy Treatment

Ionis Pharmaceuticals received FDA Orphan Drug Designation for ION337, an experimental treatment for Dravet syndrome, a rare genetic epilepsy. This designation offers benefits like tax credits and market exclusivity, supporting development but not approval, with ongoing Phase 1/2 trials.

This Wire brief sits within Fusion42's coverage of Biotech.